Full Text View
Tabular View
No Study Results Posted
Related Studies
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin
This study has been completed.
Study NCT00082407   Information provided by Amylin Pharmaceuticals, Inc.
First Received: May 6, 2004   Last Updated: November 5, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus, Type 2
Additional conditions recognized in this trial
Diabetes Mellitus
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
AC2993
Additional drug interventions recognized in this trial
Exenatide
Insulin
Insulin, Asp(B28)-
More general drug interventions related to this trial
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Amylin Pharmaceuticals, Inc.
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services